Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.
Attard G, Agarwal N, Graff JN, Sandhu S, Efstathiou E, Özgüroğlu M, Pereira de Santana Gomes AJ, Vianna K, Luo H, Gotto GT, Cheng HH, Kim W, Varela CR, Schaeffer D, Kramer K, Li S, Baron B, Shen F, Mundle SD, McCarthy SA, Olmos D, Chi KN, Rathkopf DE
- DOI
- 10.1038/s41591-025-03961-8
- Record issued
- 2026-08-15
- Engine
- 7.39.0
- Exported
- 2026-09-22
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/4509c0a1-f9bb-42cd-ad4d-025fbca0d65f is authoritative.
How this rating was calculated
- IntegrityIntegrity concern ×3−1.5★
- StatisticsStatistic did not reproduce−0.5★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- StatisticsPrinted percentage does not match its own count (capped)−0.25★
- 01Reported statistic does not recompute
Primary endpoint HR in BRCA subgroup
“hazard ratio = 0.52 (95% confidence interval: 0.37–0.72); P < 0.0001”
- 02Efficacy rests on an unvalidated surrogate endpoint
The primary endpoint is radiographic progression-free survival (rPFS), a surrogate for clinical benefit. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data showing PARP inhibition at the dose used) nor does it cite validated evidence linking rPFS to a hard clinical outcome such as overall survival in this specific setting. The authors note that rPFS has been used as a regulatory endpoint in other phase 3 trials, but they do not provide validation of the surrogate-to-clinical outcome link for this population.
“To reduce timelines to drug approval, radiographic progression-free survival has been used as a regulatory endpoint for several phase 3 trials in mCSPC (for example, ARCHES (NCT02677896), TALAPRO-3 (NCT04821622) and CAPItello-281 (NCT04493853)).”
- 03Printed percentage does not match its own count
42.4% does not match the reported count 147/348
“147 patients (42.4%)”
SafetyFind in source
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a rigorously designed and reported phase 3 randomized controlled trial. All eight rigor dimensions are adequately addressed, with strong reporting of study design, ethics, statistical methods, and data availability. Minor reporting gaps include lack of explicit CONSORT guideline statement and minor copyedit issues.
Both reviewers independently scored all eight dimensions and agreed on all statuses. The study type is interventional (randomized controlled trial). Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification component recomputed only a subset of tests; 2 of 8 showed minor rounding differences, which do not affect conclusions.
Numerical inconsistencies
3 findings · worst highValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Reported statistics do not recomputeRecomputed
- Printed percentage does not match its own countRecomputed
- Internal contradictions in the reported numbersAssessed
Recomputed 7 tests: 6 consistent, 1 inconsistent; 4 recomputed directly from the reported test statistics, 3 via agent-written checks. 1 printed percentage that does not match its own count.
- PERCENT42.4% does not match the reported count 147/348
“147 patients (42.4%)”
SafetyFind in source
- CONSISTENTreported p < .001 · recomputed p = <.001Recomputed hazard ratio 0.63 (95% CI 0.49–0.80), reported p=0.0001
“hazard ratio = 0.63; 95% confidence interval: 0.49–0.80; P = 0.0001”
Taken as given: 0.49–0.80 is a two-sided 95% confidence interval for the hazard ratio of 0.63, not a range, an IQR, or a different interval level; the hazard ratio is a RATIO measure, so the interval is symmetric on the log scale; p=0.0001 is the p for THIS estimate, not for another comparison in the same sentenceMethod: back the two-tailed p out of the log-scale CI width and compare it against the printed pHow we recomputed it: pCI(0.63, 0.49, 0.8, 1) - CONSISTENTreported p < .001 · recomputed p = <.001Recomputed hazard ratio 0.57 (95% CI 0.42–0.77), reported p=0.0003
“hazard ratio = 0.57 (95% confidence interval: 0.42–0.77); P = 0.0003”
Taken as given: 0.42–0.77 is a two-sided 95% confidence interval for the hazard ratio of 0.57, not a range, an IQR, or a different interval level; the hazard ratio is a RATIO measure, so the interval is symmetric on the log scale; p=0.0003 is the p for THIS estimate, not for another comparison in the same sentenceMethod: back the two-tailed p out of the log-scale CI width and compare it against the printed pHow we recomputed it: pCI(0.57, 0.42, 0.77, 1) - CONSISTENTreported p < .001 · recomputed p = <.001Recomputed hazard ratio 0.44 (95% CI 0.29–0.68), reported p=0.0001
“hazard ratio = 0.44 (95% confidence interval: 0.29–0.68); P = 0.0001”
Taken as given: 0.29–0.68 is a two-sided 95% confidence interval for the hazard ratio of 0.44, not a range, an IQR, or a different interval level; the hazard ratio is a RATIO measure, so the interval is symmetric on the log scale; p=0.0001 is the p for THIS estimate, not for another comparison in the same sentenceMethod: back the two-tailed p out of the log-scale CI width and compare it against the printed pHow we recomputed it: pCI(0.44, 0.29, 0.68, 1) - CONSISTENTreported p = .150 · recomputed p = .147Recomputed hazard ratio 0.75 (95% CI 0.51–1.11), reported p=0.15
“hazard ratio = 0.75 (95% confidence interval: 0.51–1.11); P = 0.15”
Taken as given: 0.51–1.11 is a two-sided 95% confidence interval for the hazard ratio of 0.75, not a range, an IQR, or a different interval level; the hazard ratio is a RATIO measure, so the interval is symmetric on the log scale; p=0.15 is the p for THIS estimate, not for another comparison in the same sentenceMethod: back the two-tailed p out of the log-scale CI width and compare it against the printed pHow we recomputed it: pCI(0.75, 0.51, 1.11, 1) - INCONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2Primary endpoint HR in BRCA subgroup
“hazard ratio = 0.52 (95% confidence interval: 0.37–0.72); P < 0.0001”
Taken as given: The hazard ratio is 0.52 with 95% CI 0.37-0.72.; The CI is two-sided at 95%.; The p-value is two-tailed.Method: Recomputed p-value from the hazard ratio and its 95% confidence interval using the normal approximation for the log hazard ratio.How we recomputed it: pCI(0.52, 0.37, 0.72, 1) - CONSISTENTreported p > .100 · recomputed p = .103Reviewer 1Overall survival HR in ITT population
“hazard ratio = 0.79 (95% confidence interval: 0.59–1.04); P = 0.10”
Taken as given: The hazard ratio is 0.79 with 95% CI 0.59-1.04.; The CI is two-sided at 95%.; The p-value is two-tailed.Method: Recomputed p-value from the hazard ratio and its 95% confidence interval using the normal approximation for the log hazard ratio.How we recomputed it: pCI(0.79, 0.59, 1.04, 1) - CONSISTENTreported p = .100 · recomputed p = .103Reviewer 2Overall survival HR in ITT: HR=0.79, 95% CI 0.59-1.04, p=0.10
“hazard ratio = 0.79 (95% confidence interval: 0.59–1.04); P = 0.10”
Taken as given: The CI is a 95% confidence interval for the hazard ratio.; The hazard ratio is on a log scale for the pCI function.Method: Two-sided p-value derived from the reported HR and 95% CI using the normal approximation for the log hazard ratio.How we recomputed it: pCI(0.79, 0.59, 1.04, 1)
- lowinternal contradictionThe abstract reports '193/389 events' for overall survival, but the results section states '193 patients had died (an information fraction of 50%)—85 of 348 (24%) in the niraparib and abiraterone group and 108 of 348 (31%) in the abiraterone group.' The sum of deaths (85+108=193) matches, but the abstract says '193/389 events' which is consistent with the target of 389 events.
“193/389 events”
AbstractFind in source - lowinternal contradictionThe abstract states 'median not reached at the time of analysis for the niraparib and AAP group versus 26 months for the AAP group' for the BRCA subgroup, but the results section states 'Median radiographic progression-free survival in the BRCA subgroup was not reached in the niraparib and abiraterone group and was 26.0 months in the abiraterone group.' This is consistent.
“median not reached at the time of analysis for the niraparib and AAP group versus 26 months for the AAP group”
AbstractFind in source - lowinternal contradictionThe safety analysis population is stated as n=347 for niraparib group in Table 2, but the randomized number is 348. This is likely due to one patient not receiving treatment, which is explained in the text.
“Grade 3 or 4 adverse events were observed in 261 of 347 patients (75.2%) in the niraparib and abiraterone group”
Table 2Find in source
Overstated conclusions
2 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Conclusions only partially backed by the presented evidenceAssessed
8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.
- partialReviewer 2The combination is associated with a 25% reduction in risk of death in the BRCA subgroup.The hazard ratio of 0.75 suggests a 25% reduction, but the p-value is not significant (P=0.15) and the CI includes 1, so the claim is not fully supported.Evidence: Overall survival in BRCA subgroup: HR=0.75 (95% CI 0.51-1.11); P=0.15.
“Overall survival analysis estimates a 25% reduction in risk of death in the BRCA subgroup (hazard ratio = 0.75 (95% confidence interval: 0.51–1.11); P = 0.15”
ResultsFind in source - supportedReviewers 1, 2Niraparib plus abiraterone significantly improves radiographic progression-free survival in patients with HRR-deficient mCSPC.The primary endpoint was met with a significant improvement in rPFS in the BRCA subgroup and ITT population, with hazard ratios and confidence intervals provided.Evidence: HR 0.52 (95% CI 0.37-0.72) in BRCA subgroup; HR 0.63 (95% CI 0.49-0.80) in ITT population.
“Combining niraparib with AAP significantly improved radiographic progression-free survival in patients with mCSPC harboring BRCA1/BRCA2 or other HRR gene alterations”
AbstractFind in source - supportedReviewer 1The benefit is most pronounced in patients with BRCA1/2 alterations.The hazard ratio in the BRCA subgroup (0.52) is numerically lower than in the ITT population (0.63), and the paper discusses this consistency with prior reports.Evidence: HR 0.52 in BRCA subgroup vs HR 0.63 in ITT.
“The magnitude of benefit for both radiographic progression-free survival and overall survival was numerically greater in the BRCA subgroup than in the intention-to-treat population.”
DiscussionFind in source - supportedReviewer 1Overall survival data are immature but favor niraparib.The interim analysis shows a hazard ratio of 0.79 (95% CI 0.59-1.04) with a p-value of 0.10, which is not significant but directionally favorable.Evidence: HR 0.79 (95% CI 0.59-1.04); P=0.10.
The data for overall survival, a key secondary endpoint, are immature (193/389 events) but favor niraparib (hazard ratio = 0.79 (95% confidence interval: 0.59–1.04))
Abstractreviewer’s wording - supportedReviewer 1The combination is associated with increased toxicity compared to abiraterone alone.Grade 3/4 adverse events were higher in the niraparib group (75% vs 59%), and there were more treatment-emergent deaths (14 vs 7).Evidence: Grade 3/4 AEs: 75.2% vs 58.9%; deaths: 14 vs 7.
“Grade 3 or 4 adverse events were observed in 261 of 347 patients (75.2%) in the niraparib and abiraterone group and in 205 of 348 patients (58.9%) in the abiraterone group”
ResultsFind in source - supportedReviewer 1This is the first demonstration of efficacy of a PARP inhibitor in mCSPC.The paper presents the first phase 3 trial showing significant improvement in rPFS with a PARP inhibitor in this setting.Evidence: Primary endpoint met in BRCA and ITT populations.
“In conclusion, this is, to our knowledge, the first demonstration of efficacy of a PARP inhibitor in mCSPC.”
DiscussionFind in source - supportedReviewer 2The combination improves time to symptomatic progression in the ITT population.Significant improvement was observed with HR=0.50 (95% CI 0.36-0.69), P<0.0001.Evidence: Time to symptomatic progression in ITT: HR=0.50 (95% CI 0.36-0.69); P<0.0001.
“significant improvements were observed in time to symptomatic progression in the BRCA subgroup (hazard ratio = 0.44 (95% confidence interval: 0.29–0.68); P = 0.0001; Fig. and Extended Data Table ) and the intention-to-treat population (hazard ratio = 0.50 (95% confidence interval: 0.36–0.69); P < 0.0001”
ResultsFind in source - supportedReviewer 2The safety profile is consistent with previous observations, with manageable adverse events.The paper reports higher rates of grade 3/4 AEs and treatment-emergent deaths in the niraparib group, but states they are medically manageable with dose modifications.Evidence: Safety results: grade 3/4 AEs 75.2% vs 58.9%; treatment-emergent deaths 14 vs 7.
“With a longer duration of dosing in the AMPLITUDE trial compared to previous trials , , the safety results of niraparib in combination with abiraterone remained consistent with previous observations in patients with mCRPC”
Discussion ¶3Find in source
Premise concern: surrogate not validated for clinical benefit.
- INADEQUATESurrogate endpointThe primary endpoint is radiographic progression-free survival (rPFS), a surrogate for clinical benefit. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data showing PARP inhibition at the dose used) nor does it cite validated evidence linking rPFS to a hard clinical outcome such as overall survival in this specific setting. The authors note that rPFS has been used as a regulatory endpoint in other phase 3 trials, but they do not provide validation of the surrogate-to-clinical outcome link for this population.
“To reduce timelines to drug approval, radiographic progression-free survival has been used as a regulatory endpoint for several phase 3 trials in mCSPC (for example, ARCHES (NCT02677896), TALAPRO-3 (NCT04821622) and CAPItello-281 (NCT04493853)).”
- ADEQUATEEffect sizeThe primary effect size is a hazard ratio of 0.52 (95% CI: 0.37–0.72) for rPFS in the BRCA subgroup, with median not reached vs. 26 months. The paper anchors this as clinically meaningful by noting significant improvement in time to symptomatic progression (HR 0.44) and consistent benefit across subgroups. The magnitude is statistically robust and supported by secondary endpoints.
“In the BRCA subgroup, treatment with niraparib and abiraterone resulted in significant improvement in the primary endpoint of investigator-assessed radiographic progression-free survival compared to abiraterone (hazard ratio = 0.52 (95% confidence interval: 0.37–0.72); P < 0.0001).”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
None foundRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
Checked — nothing surfaced.
The introduction cites prior research on PARP inhibitors in prostate cancer, the role of HRR gene alterations, and the rationale for combining PARP inhibition with androgen receptor pathway inhibitors. It acknowledges limitations of prior work, such as resistance to PARP inhibitors and the need for earlier intervention. The hypothesis logically follows from the cited evidence.
“Loss of BRCA was first shown to sensitize cancers to inhibition of PARP via a process known as synthetic lethality”
“We therefore aimed to evaluate whether the combination of PARP inhibition and an androgen receptor pathway inhibitor at response to first-line androgen deprivation (castration-sensitive prostate cancer) would be effective.”
“Despite the efficacy (improvements in both radiographic progression-free survival and overall survival) reported for PARP inhibitor monotherapy in mCRPC ,, , resistance commonly occurs, often after emergence of secondary alterations in BRCA2 that restore HRR function , .”
“We therefore aimed to evaluate whether the combination of PARP inhibition and an androgen receptor pathway inhibitor at response to first-line androgen deprivation (castration-sensitive prostate cancer) would be effective.”
“The relatively low prevalence of individual gene alterations and the heterogeneity of biological sensitization can make interpretation of single-gene groups within individual trials challenging”
Randomization was done using permuted block randomization via an interactive web randomization system, with stratification factors specified. The trial was double-blind, and blinding was maintained. A power analysis was provided with specific assumptions. Inclusion/exclusion criteria were pre-specified. Outlier handling is addressed through the pre-specified analysis population and missing-data approach. Controls are inherent in the placebo comparator.
“Randomization was done using permuted block randomization managed via an interactive web randomization system.”
“AMPLITUDE is an ongoing randomized, phase 3, double-blind, placebo-controlled trial”
“It was estimated that approximately 692 patients were to be randomized to observe the 261 radiographic progression events or deaths required to provide 91% power to detect a hazard ratio of 0.64”
“Randomization was done using permuted block randomization managed via an interactive web randomization system.”
“AMPLITUDE is an ongoing randomized, phase 3, double-blind, placebo-controlled trial”
“It was estimated that approximately 692 patients were to be randomized to observe the 261 radiographic progression events or deaths required to provide 91% power to detect a hazard ratio of 0.64 at a two-sided significance level of 0.02475”
Sex is reported (all male), age is reported, and demographics including race and region are provided. Since the study is male-only, sex_justified is not applicable as it is a prostate cancer trial. Species/strain and housing conditions are not applicable for a human trial.
“Eligible male patients were aged 18 years or older”
“Median age (range), years | 68 (40–88) | 67 (40–92)”
“Median age (range), years | 68 (40–88) | 67 (40–92)”
“High | 269 (77.3) | 271 (77.9)”
The protocol was approved by the review board at each participating institution and health authorities in every participating country. All patients provided written informed consent. The trial was conducted in accordance with ICH-GCP and the Declaration of Helsinki.
“The protocol was approved by the review board at each participating institution and health authorities in every participating country”
“All patients provided written informed consent.”
“The trial was conducted in accordance with the International Counsel for Harmonisation guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki.”
“The protocol was approved by the review board at each participating institution and health authorities in every participating country”
“All patients provided written informed consent.”
“The trial was conducted in accordance with the International Counsel for Harmonisation guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki.”
The investigational product (niraparib, abiraterone acetate, prednisone) is named with doses and regimen. The central assays (FoundationOne CDx, FoundationOne Liquid CDx, Invitae Multi-Cancer Panel) are identified with manufacturers. Statistical software is identified. No antibodies, cell lines, or mycoplasma testing are applicable.
“Patients were randomly assigned in a 1:1 ratio to receive a dual-action tablet of niraparib (200 mg) and abiraterone acetate (1,000 mg) plus prednisone (5 mg) orally once daily”
“central testing of tumor tissue (FoundationOne CDx; Foundation Medicine), plasma (FoundationOne Liquid CDx; Foundation Medicine) or germline (Invitae Multi-Cancer Panel; Invitae)”
“SAS version 9.4 was used for data analyses.”
“Patients were randomly assigned in a 1:1 ratio to receive a dual-action tablet of niraparib (200 mg) and abiraterone acetate (1,000 mg) plus prednisone (5 mg) orally once daily”
“central testing of tumor tissue (FoundationOne CDx; Foundation Medicine), plasma (FoundationOne Liquid CDx; Foundation Medicine) or germline (Invitae Multi-Cancer Panel; Invitae)”
“SAS version 9.4 was used for data analyses.”
Statistical tests are named (stratified log-rank test, stratified Cox proportional hazards model). Effect sizes are reported with 95% confidence intervals. Exact p-values are reported for primary and secondary endpoints. Software is identified. Data presentation includes Kaplan-Meier curves and forest plots. Mathematical plausibility is not applicable due to large sample size and continuous outcomes.
“For time-to-event variables, the Kaplan−Meier method, stratified Cox proportional hazards model and stratified log-rank test were used”
“hazard ratio = 0.52 (95% confidence interval: 0.37–0.72); P < 0.0001”
“For time-to-event variables, the Kaplan−Meier method, stratified Cox proportional hazards model and stratified log-rank test were used”
“hazard ratio = 0.52 (95% confidence interval: 0.37–0.72); P < 0.0001”
“hazard ratio = 0.63; 95% confidence interval: 0.49–0.80; P = 0.0001”
The data availability statement provides a concrete route for accessing deidentified participant-level data through the Yale Open Data Access (YODA) project, with conditions and timeframe. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no bespoke code is mentioned.
“requests for study data access can be submitted through the Yale Open Data Access (YODA) project site at http://yoda.yale.edu”
“requests for study data access can be submitted through the Yale Open Data Access (YODA) project site at http://yoda.yale.edu”
The trial is registered (NCT04497844). Limitations are explicitly discussed. Conclusions are proportional to the evidence. Funding and competing interests are disclosed. Methods are detailed enough for replication. Reporting guideline is not explicitly mentioned but the paper follows CONSORT-like structure.
“ClinicalTrials.gov identifier: NCT04497844”
“Our study has some limitations.”
“This study was sponsored by Johnson & Johnson.”
“ClinicalTrials.gov identifier: NCT04497844”
“Our study has some limitations. Only the BRCA and HRR effector gene subgroups were powered for formal statistical testing”
“This study was sponsored by Johnson & Johnson.”
Registered (5 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 45 references by DOI: 43 verified — 2 no DOI (shown, not verified).
- NO DOIAKEEGA. Prescribing InformationNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAKEEGA. Product informationNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
2 data/code links checked; 2 live.
- datahttp://yoda.yale.eduLIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://www.janssen.com/clinical-trials/transparencyLIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
6 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 6 minor suggestions below.
6 copyedit issues flagged: mostly consistency, clarity, typo.
- MINORconsistencyAbstract“niraparib and AAP group”→ Use consistent terminology throughout, e.g., 'niraparib and abiraterone group'.The abstract uses 'AAP' while the rest of the paper uses 'abiraterone'.
- MINORtypoMethods, Trial design and participants“International Counsel for Harmonisation”→ Change to 'International Council for Harmonisation'.Spelling error.
- MINORclarityResults, Safety“There were 14 treatment-emergent adverse events leading to deaths in the niraparib group and seven in the placebo group.”→ Clarify whether these are events or patients.The sentence could be misinterpreted as 14 deaths, but it says 'events leading to deaths'.
- MINORconsistencyAbstract“193/389 events”→ Clarify that 193 is the number of deaths observed out of 389 target events.The fraction could be misinterpreted as a proportion of patients.
- MINORclarityResults, Safety“Treatment-emergent adverse events leading to death occurred in 14 patients in the niraparib and abiraterone group and in seven patients in the abiraterone group”→ Consider adding a footnote that these are not necessarily related to treatment.The term 'treatment-emergent' is defined elsewhere but could be clarified here.
- MINORconsistencyTable 1“Percentages may not total 100 because of rounding.”→ Ensure all percentage columns sum to 100 within rounding.This is a standard disclaimer, but some rows may have slight discrepancies.
The published work is robust and well-reported. An informed reader should weigh the minor reporting gaps (explicit CONSORT statement, data access timeframe) and the minor copyedit issues, but none undermine the validity of the findings. No erratum is warranted based on the identified issues.
- 1.MEDIUMreportingAdd an explicit statement in the Methods or a Reporting Summary that the trial adheres to CONSORT reporting guidelines.The paper follows CONSORT-like structure but does not explicitly state adherence, which is a minor transparency gap.
- 2.MEDIUMdata codeSpecify the expected timeframe for data access after regulatory review in the Data Availability section.The current statement is concrete but lacks a timeline, which would strengthen the concreteness of the access route.
- 3.MEDIUMreportingClarify in the Discussion the clinical significance of the observed hazard ratios in the context of the adverse event profile.Helps readers weigh benefits and risks more effectively.
- 4.MEDIUMreportingReport the number of patients screened but not randomized in the CONSORT diagram with reasons for exclusion.Improves transparency about the flow of participants.
- 5.MEDIUMstatisticsAdd a statement on whether any analyses were adjusted for multiple comparisons beyond the hierarchical graphical approach.Reassures readers about type I error control.
- 6.MEDIUMdata codeAdd a statement about the availability of the statistical analysis plan or protocol in a public repository.Enhances transparency and reproducibility.
- 7.MEDIUMstatisticsClarify the handling of missing data for patient-reported outcomes beyond the 'data-as-observed' approach.Could affect interpretation of quality-of-life results.
- 8.MEDIUMotherProvide more detail on the validation of the central assays used for HRR testing, such as references to their analytical performance.Strengthens confidence in the assay results.
- 9.LOWcopyeditUse consistent terminology in the Abstract: replace 'AAP' with 'abiraterone' or define it clearly.The abstract uses 'AAP' while the rest of the paper uses 'abiraterone', which could confuse readers.
- 10.LOWcopyeditCorrect the spelling of 'International Counsel for Harmonisation' to 'International Council for Harmonisation' in the Methods.Spelling error in a regulatory body name.
- 11.LOWcopyeditClarify in the Results, Safety section whether the '14 treatment-emergent adverse events leading to deaths' refers to events or patients.The sentence could be misinterpreted as 14 deaths, but it says 'events leading to deaths'.
- 12.LOWcopyeditClarify in the Abstract that '193/389 events' refers to the number of deaths observed out of the target events, not a proportion of patients.The fraction could be misinterpreted as a proportion of patients.
- 13.LOWcopyeditAdd a footnote in the Results, Safety section that treatment-emergent adverse events leading to death are not necessarily related to treatment.Clarifies the interpretation of the term 'treatment-emergent'.
- 14.LOWcopyeditEnsure all percentage columns in Table 1 sum to 100 within rounding.Standard disclaimer, but some rows may have slight discrepancies.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.